Publications by authors named "David Limburg"

Claim this Profile
D
Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity.
Mark E Schnute, Huixian Wu, John I Trujillo, Wei Li, David Jonathan Wasilko, David C Limburg

J Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water Molecule.
Mark E Schnute, Gary M Chinigo, Kentaro Futatsugi, Masaya Yamaguchi, Scott W Bagley, David C Limburg

ACS Med Chem Lett· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
Andrew Fensome, Catherine M Ambler, Eric Arnold, Mary Ellen Banker, James D Clark, David C Limburg

Bioorg Med Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
Andrew Fensome, Catherine M Ambler, Eric Arnold, Mary Ellen Banker, Matthew F Brown, David C Limburg

J Med Chem· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Seungil Han, Robert M Czerwinski, Nicole L Caspers, David C Limburg, WeiDong Ding

Biochem J· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
Christoph W Zapf, Brian S Gerstenberger, Li Xing, David C Limburg, David R Anderson

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life.
Jane L Wang, David Limburg, Matthew J Graneto, John Springer, Joseph Rogier Bruce Hamper

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: the three microdose candidates.
Jane L Wang, Karl Aston, David Limburg, Cindy Ludwig, Ann E Hallinan

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
Jane Wang, David Limburg, Jeff Carter, Gabriel Mbalaviele, James Gierse

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herbivore population suppression by an intermediate predator, Phytoseiulus macropilis, is insensitive to the presence of an intraguild predator: an advantage of small body size?
Jay A Rosenheim, David D Limburg, Ramana G Colfer, Valerie Fournier, Cynthia L Hsu

Oecologia· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of chiral bicyclic proline FKBP12 ligands.
David C Limburg, Bert E Thomas, Jia-He Li, Mike Fuller, Dawn Spicer

Bioorg Med Chem Lett· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effects.
Douglas E Wilkinson, Bert E Thomas, David C Limburg, Agnes Holmes, Hansjorg Sauer

Bioorg Med Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroprotective effects of inhibitors of dipeptidyl peptidase-iV in vitro and in vivo.
Yong-Qian Wu, David C Limburg, Douglas E Wilkinson, Paul Jackson, Joseph P Steiner

Adv Exp Med Biol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of non-peptidic cyclophilin ligands.
Yong-Qian Wu, Sergei Belyakov, Chi Choi, David Limburg, Bert E Thomas IV

J Med Chem· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.
Gregory S Hamilton, Yong-Qian Wu, David C Limburg, Douglas E Wilkinson, Mark J Vaal

J Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands.
Yong-Qian Wu, Douglas E Wilkinson, David Limburg, Jia-He Li, Hansjorg Sauer

J Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.
Chi Choi, Jia-He Li, Mark Vaal, Christine Thomas, David Limburg

Bioorg Med Chem Lett· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis